News

Cobimetinib is a selective inhibitor of MEK that was discovered by Exelixis and is the subject of a worldwide collaboration agreement between Exelixis and Genentech, a member of

The deal is part of the Belgian firm’s intention to expand the global footprint of C-Cure to treat ischemic heart failure. As part of the deal, Celyad will

The programme aims to support research into areas of medical need in cardiovascular medicine. Four grants of up to €400,000 each will be awarded to researchers or clinicians

With this approval, the drug can be used as monotherapy in people who start treatment for the first time or convert from other antiepileptic drugs (AEDs) to Aptiom.

Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove LDL-C or bad cholesterol from

With the completion of the deal, Perrigo now has rights to the nicotine replacement therapies of both GSK and Novartis, NiQuitin and Nicotinell. The deal also includes Novartis’s

Derived from the cell wall fractionation of non-pathogenic bacteria, MCNA is a biologic therapy developed to provide high risk non-muscle invasive bladder cancer patients who are refractory to

According to the company, MRX-I is claimed to offer physicians and patients a safer and better tolerated therapeutic option compared to the currently available oxazolidinone agents. MicuRx Pharmaceuticals

QIMR is focused on research of cancer, infectious diseases, mental health and a range of complex disorders. As part of the deal, BMS will be solely responsible for